If rapamycin works in MS does it mean the T-reg hypothesis is back on the table? I suspect not. #ResearchSpeak https://t.co/owe3tSaUeU pic.twitter.com/tb6ODTluWn— Gavin Giovannoni (@GavinGiovannoni) September 18, 2018
More hype over substance! #ClinicSpeak Stem cell therapy for neurological disorders: A focus on aging. https://t.co/cJKtOHELbx pic.twitter.com/zIQnUi5v3D— Gavin Giovannoni (@GavinGiovannoni) September 18, 2018
An interesting observation that photophobia (exposure to bright light is uncomfortable) is quite common in MSers. This is my personal observation as well. I have several patients who can't tolerate fluorescent light ad wear sunglasses. #ClinicSpak https://t.co/5YNkBZTyPg pic.twitter.com/ysnlRgRze8— Gavin Giovannoni (@GavinGiovannoni) September 19, 2018
MSers on DMF (Tecfidera) need to remain vigilant about opportunistic or other infections. DMF is an immunosuppressive drug. #ClinicSpeak Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a MS patient. https://t.co/IWogMmz72i pic.twitter.com/VsMocTmEaM— Gavin Giovannoni (@GavinGiovannoni) September 20, 2018
A fascinating case of Zika virus CNS infection in an MSer. Could the MS have made this person more susceptible to Zika infection? #NeuroSpeak We need to be more vigilant about dual pathologies in MS. https://t.co/gepuDijrqi pic.twitter.com/uugXYmWuKJ— Gavin Giovannoni (@GavinGiovannoni) September 20, 2018
Did you know that there is a naturally occurring change in the MS Walking Scale-12 scores over time in MSers? Are you surprised? MS is a progressive disease and causes worsening disability. Talk about stating the bleeding obvious. #ClinicSpeak https://t.co/wydLHtXg1F pic.twitter.com/u6gnBk0bFe— Gavin Giovannoni (@GavinGiovannoni) September 20, 2018
Do you really think ablating CNS lymphatics is a realistic treatment option for MS? #ResearchSpeak CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. https://t.co/f9mk5KwOj8 pic.twitter.com/vlJByg3LoB— Gavin Giovannoni (@GavinGiovannoni) September 20, 2018
Wow! A very depressing paper showing how sensitive MSers are to the costs of DMTs in the US. In socialist healthcare systems this does not happen. #PoliticalSpeal Cost Sharing of DMTs as Policy Lever to Improve DMTs' Access in MS https://t.co/0DF2CgTnea pic.twitter.com/Y4pJqJvVqq— Gavin Giovannoni (@GavinGiovannoni) September 21, 2018
Liver injury with drugs used to treat MS data from the FDA adverse event reporting system. Interesting that alemtuzumab is singled out amongst the monoclonals. Could it be due to CMV hepatitis? #ClinicSpeak #NeuroSpeak https://t.co/pjaISEpXd9 pic.twitter.com/A1qDxVX4zT— Gavin Giovannoni (@GavinGiovannoni) September 21, 2018